CN103547280B - 用于药物组合物的巨噬细胞活化因子 - Google Patents

用于药物组合物的巨噬细胞活化因子 Download PDF

Info

Publication number
CN103547280B
CN103547280B CN201280024137.XA CN201280024137A CN103547280B CN 103547280 B CN103547280 B CN 103547280B CN 201280024137 A CN201280024137 A CN 201280024137A CN 103547280 B CN103547280 B CN 103547280B
Authority
CN
China
Prior art keywords
protein
composition
gcmaf
cancer
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280024137.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN103547280A (zh
Inventor
山本信人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EFRANAT Ltd
Original Assignee
EFRANAT Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46968677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103547280(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by EFRANAT Ltd filed Critical EFRANAT Ltd
Publication of CN103547280A publication Critical patent/CN103547280A/zh
Application granted granted Critical
Publication of CN103547280B publication Critical patent/CN103547280B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/082—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • C12N11/087—Acrylic polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201280024137.XA 2011-04-07 2012-04-05 用于药物组合物的巨噬细胞活化因子 Expired - Fee Related CN103547280B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472642P 2011-04-07 2011-04-07
US61/472,642 2011-04-07
PCT/IL2012/000159 WO2012137199A1 (en) 2011-04-07 2012-04-05 Macrophage activating factor for pharmaceutical compositions

Publications (2)

Publication Number Publication Date
CN103547280A CN103547280A (zh) 2014-01-29
CN103547280B true CN103547280B (zh) 2017-06-09

Family

ID=46968677

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280024137.XA Expired - Fee Related CN103547280B (zh) 2011-04-07 2012-04-05 用于药物组合物的巨噬细胞活化因子

Country Status (7)

Country Link
US (3) US20140030215A1 (enExample)
EP (1) EP2694088B1 (enExample)
JP (1) JP6113712B2 (enExample)
CN (1) CN103547280B (enExample)
AU (1) AU2012240945B2 (enExample)
CA (1) CA2832487A1 (enExample)
WO (1) WO2012137199A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014279627A1 (en) * 2013-06-09 2015-12-03 Efranat Ltd. Compositions comprising Gc- macrophage activating factor and uses thereof
AT518622A1 (de) * 2016-04-21 2017-11-15 Hg Pharma Gmbh Dimerer Komplex aus selektiv deglycosyliertem Vitamin D bindenden Protein (GcMAF) und Cholecalciferol (Calciol) und Verfahren zu dessen Herstellung
WO2018025270A1 (en) * 2016-08-04 2018-02-08 Efranat Ltd. Enriched modified vitamin d binding protein compositions and use thereof
AU2021398261A1 (en) * 2020-12-08 2023-07-06 Saisei Pharma Co., Ltd. Macrophage activator

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326749A (en) * 1989-11-20 1994-07-05 Nobuto Yamamoto Macrophage activating factor from vitamin D binding protein
CN1191567A (zh) * 1995-06-07 1998-08-26 山本信人 由克隆的维生素d结合蛋白衍生的巨噬细胞激活因子

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5177001A (en) * 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated mammalian vitamin D-binding protein to a potent macrophage activating factor
US5177002A (en) 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor
US5814225A (en) 1994-06-09 1998-09-29 Shanbrom Technologies Llc Iodinated gel filtration media for disinfecting protein solutions
US6096216A (en) 1994-06-09 2000-08-01 American National Red Cross Iodinated matrices for disinfecting biological fluids
AU2002246849A1 (en) * 2000-11-09 2002-08-06 Northeastern Ohio Universities College Of Medicine Agents and methods for promoting bone growth
US6806355B2 (en) * 2001-08-14 2004-10-19 Statens Serum Institut Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
WO2004005466A2 (en) * 2002-07-03 2004-01-15 Illumigen Biosciences Methods and compositions for diagnosing hepatocellular carcinoma
US8034773B2 (en) * 2004-02-05 2011-10-11 Arizona Biomedical Research Commission Immunostimulatory compositions and uses thereof
WO2005077044A2 (en) * 2004-02-05 2005-08-25 ARIZONA BOARD OF REGENTS, acting for on behalf of ARIZONA STATE UNIVERSITY Rational design and engineering of proteins and peptides for immunomodulation
AU2010289901A1 (en) 2009-08-22 2012-03-15 Charles Knezevich Tumoricidal, bactericidal, or viricidal macrophage activation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326749A (en) * 1989-11-20 1994-07-05 Nobuto Yamamoto Macrophage activating factor from vitamin D binding protein
CN1191567A (zh) * 1995-06-07 1998-08-26 山本信人 由克隆的维生素d结合蛋白衍生的巨噬细胞激活因子

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
用快速高效液相色谱系统分离纯化G c 蛋白;李兆隆等;《中国法医学杂志》;19961231;第11卷(第3期);第135-139页 *

Also Published As

Publication number Publication date
EP2694088A4 (en) 2014-12-10
WO2012137199A1 (en) 2012-10-11
US20140030215A1 (en) 2014-01-30
EP2694088A1 (en) 2014-02-12
CA2832487A1 (en) 2012-10-11
US20170173115A1 (en) 2017-06-22
EP2694088B1 (en) 2017-06-07
JP2014511857A (ja) 2014-05-19
JP6113712B2 (ja) 2017-04-12
AU2012240945A1 (en) 2013-10-24
US20150361151A1 (en) 2015-12-17
AU2012240945B2 (en) 2017-03-16
CN103547280A (zh) 2014-01-29

Similar Documents

Publication Publication Date Title
AU781135B2 (en) Recombinant human mannan-binding lectin
US20200246420A1 (en) pHLIP® peptide-mediated epitope tethering at cell surfaces
JP7505980B2 (ja) Ｃ３ｂ結合ポリペプチド
PT2040728E (pt) Fkbp-l e seus usos como inibidores de angiogénese
AU2013243950A1 (en) Modified polynucleotides
CZ386392A3 (en) Alpha interferon
BR112020004567A2 (pt) polipeptídeos para o tratamento de doenças
CN103547280B (zh) 用于药物组合物的巨噬细胞活化因子
WO2017044855A2 (en) Cell penetrating peptides that inhibit irf5 nuclear localization
CN103153333B (zh) 补体因子h的纯化方法
BR112021008797A2 (pt) Polipeptídeos para o tratamento de síndromes de estresse, imunorreação e derrame
CA2092720C (en) Macrophage activating factor from vitamin d binding protein
JP2017525394A (ja) ディスインテグリンバリアントとその医薬用途
CA3146948A1 (en) Method for increasing lymphocyte count by using il-7 fusion protein in tumors
KR20190113886A (ko) 바이러스 또는 vlp의 재표적화
US20200030413A1 (en) Methods and pharmaceutical compositions for the treatment of kidney cancer
JP7066409B2 (ja) 癌または転移性疾患の治療または予防における環状アセチルコリンエステラーゼｃ末端ペプチド
HK1194290A (en) Macrophage activating factor for pharmaceutical compositions
CN115989238A (zh) 包含il-2蛋白和cd80蛋白片段或其变体的融合蛋白及其用途
KR20120095063A (ko) ＩＬ-27로 유도된 ｐ53을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
CN110016082B (zh) MIP3α-FGFR1-PD1/Fc融合蛋白及其核酸分子和应用
KR20250122028A (ko) 신경 퇴행성 질환 유발 인자 제거용 신규 융합단백질 및 이의 용도
AU2004316095A1 (en) Anticancer agent containing BL angiostatin
WO2007037514A1 (ja) ヘパリン結合性上皮増殖因子様増殖因子の新規医薬用途
WO2009030087A1 (fr) Fonctions et utilisations de la protéine 4 se liant à la phosphatidyléthanolamine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1194290

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170609

Termination date: 20180405

CF01 Termination of patent right due to non-payment of annual fee
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1194290

Country of ref document: HK